Ambrx Biopharma Inc (DELISTED) (AMAM:DL)
27.99
+0.01
(+0.04%)
USD |
NASDAQ |
Mar 06, 16:00
Ambrx Biopharma Shareholders Equity (Quarterly): 242.40M for Sept. 30, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 242.40M |
| June 30, 2023 | 250.38M |
| March 31, 2023 | 182.59M |
| December 31, 2022 | 117.85M |
| June 30, 2022 | 141.89M |
| Date | Value |
|---|---|
| December 31, 2021 | 189.97M |
| June 30, 2021 | 192.80M |
| June 30, 2021 | 192.80M |
| December 31, 2020 | -139.43M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-139.43M
Minimum
Dec 2020
250.38M
Maximum
Jun 2023
152.36M
Average
189.97M
Median
Dec 2021
Shareholders Equity (Quarterly) Benchmarks
| Johnson & Johnson | 70.16B |
| Axonics Inc | 664.49M |
| Harpoon Therapeutics Inc (DELISTED) | 4.541M |
| Merck & Co Inc | 44.50B |
| RayzeBio inc (DELISTED) | 575.32M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 271.50M |
| Total Liabilities (Quarterly) | 29.10M |
| Current Ratio | 12.80 |